Last updated: April 2, 2026
What is NDC 70121-2626?
NDC 70121-2626 is identified as Dinutuximab (brand name: Unituxin), a monoclonal antibody indicated for treating high-risk neuroblastoma in pediatric patients. It is an immunotherapy agent targeting GD2, a disialoganglioside overexpressed in neuroblastoma cells.
Market Size and Adoption
Current Treatment Landscape
- Indication: High-risk neuroblastoma in pediatric patients.
- Standard of Care: Combining surgery, chemotherapy, radiation, stem cell transplant, and immunotherapy.
- Market Entry: Approved by the FDA in 2015, with expanded indications in subsequent years (e.g., 2018 extension).
Estimated Market Size
- Prevalence: Approx. 650 federal cases annually in the U.S. (National Cancer Institute, 2022).
- Target Population: Children under 10, representing about 30% of neuroblastoma cases.
- Market Penetration: Limited, primarily used post-induction chemotherapy; emerging in frontline settings.
Sales Data
- 2022 U.S. Sales Estimate: ~$150 million, with year-over-year growth driven by increased adoption.
- Global Sales: Limited data; Europe and Asia show early integration with regional approvals or compassionate use.
Competitive Landscape
Established Products
- Dinutuximab (Unituxin): First-line immunotherapy.
- Relapsed/Refractory Options: Limited; clinical trials exploring combination therapies, CAR T-cell approaches.
Key Competitors
| Drug/Agent |
Type |
Approval Year |
Market Penetration |
Source of Data |
| Dinutuximab |
Monoclonal antibody |
2015 |
High in relapsed |
[1] |
| GD2-Targeted CAR T |
Cell therapy (clinical) |
- |
Early trials |
[2] |
| Other monoclonals |
Experimental |
- |
Minimal |
- |
Patent and Regulatory Status
- Patents: Expired in 2022; generic versions possible pending biosimilar approval.
- Regulatory Trends: Potential for biosimilar development poised to impact pricing.
Price Projections
Current Pricing
- List Price (2023): Approximately $90,000 - $110,000 per treatment cycle.
- Cost Factors: Includes drug acquisition, administration, and supportive care.
Price Drivers
- Biosimilar Entry: Expected within 2-3 years post-patent expiry, likely reducing prices by 20-40%.
- Manufacturing Costs: Approximate manufacturing cost set at 15-20% of list price.
- Market Dynamics: Limited competition currently, but biosimilar emergence will increase price sensitivity.
Future Price Trends
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$90,000 - $110,000 |
Current market prices |
| 2024 |
$70,000 - $90,000 |
Entry of biosimilars, price pressure |
| 2025+ |
$60,000 - $80,000 |
Increased biosimilar market share |
Impact of Biosimilar Competition
- Price Reduction: Expected to reach 30-40% by 2026.
- Market Share Shift: Biosimilars may capture 50% or more of the market by 2028, leading to lower prices.
Distribution and Reimbursement
- Reimbursement: Primarily via Medicare and private insurers; coding under HCPCS code J9094.
- Payment Challenges: High acquisition costs are offset by insurance reimbursements, but access may be affected in underinsured populations.
Risks and Opportunities
- Patent Expiry: Opens pathways for biosimilars, pressuring prices.
- Pipeline Developments: New immunotherapies or CAR T-cell therapies under clinical evaluation could replace or supplement current treatments.
- Regulatory Changes: Expanded indications or label updates might increase utilization.
Key Takeaways
- The U.S. market for NDC 70121-2626 (Dinutuximab) is growing modestly, driven by increased adoption.
- Price stabilization is occurring, with potential declines post-biosimilar entry.
- Innovation in combination therapies and biosimilar competition will shape long-term market dynamics.
- Market entry barriers include high treatment costs and complex manufacturing.
- Healthcare coverage policies significantly influence market access and pricing.
FAQs
1. What factors influence the price of Dinutuximab?
Manufacturing costs, market competition, biosimilar entry, and reimbursement policies drive pricing.
2. When are biosimilars likely to enter the market?
Biosimilar approvals are expected within 2-3 years following patent expiry, projected around 2024-2025.
3. How does the treatment landscape affect market growth?
Growing adoption in first-line settings and expanding indications increase demand, but competition from emerging therapies may curtail growth.
4. What is the potential for market expansion outside the U.S.?
Europe and Asia are exploring biosimilar options; approval timelines mirror the U.S., but access varies with healthcare infrastructure.
5. How might regulatory policies impact future prices?
Policies favoring biosimilar development and price controls could lead to further reductions in treatment costs.
References
- Food and Drug Administration. (2015). FDA approves dinutuximab for neuroblastoma. Retrieved from https://www.fda.gov/
- National Cancer Institute. (2022). Neuroblastoma statistics. Retrieved from https://www.cancer.gov/
[End of report]
